Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 241-250 of 603 for hematology

Edit search filters
  1. Atezolizumab With Or Without Cobimetinib In Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery Or Gallbladder Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. S1216, Phase III ADT+TAK-700 Vs. ADT+Bicalutamide For Metastatic Prostate Cancer

    Rochester, MN

  3. Testing The Addition Of A New Drug, Venetoclax, To The Usual Treatment (Ibrutinib And Rituximab) For Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    Jacksonville, FL, Rochester, MN

  4. Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

    Rochester, MN

  5. A Study Using Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Post Cardiopulmonary Bypass Surgery Clotting Problems and Bleeding

    Rochester, MN

  6. Bortezomib, Rituximab, and Dexamethasone with or without Temsirolimus in Treating Patients with Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

    Rochester, MN

  7. Vorinostat, Temozolomide, or Bevacizumab in Combination with Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients with Newly Diagnosed High-Grade Glioma

    Rochester, MN

  8. Phase II Venetoclax, Obinutuzumab And Bendamustine In High Tumor Burden Follicular Lymphoma As Front Line Therapy

    Rochester, MN

  9. Study Evaluating The Safety And Effectiveness Of JCARH125 In Subjects With Relapsed And/or Refractory Multiple Myeloma (EVOLVE)

    Rochester, MN

  10. A Study In Subjects With Relapsed And Refractory Multiple Myeloma Receiving Carfilzomib In Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (ARROW)

    Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer